Emerging research suggests that GLP-1 receptor agonists may offer protective benefits against fragility fractures, particularly in people with obesity or type 2 diabetes, challenging previous concerns about weight-loss medications weakening bones.
New research presented at the American Orthopaedic Foot & Ankle Society annual meeting suggests GLP-1 receptor agonists may do more than help with weight loss and glucose control: they may also be linked to a lower risk of fragility fractures in people with obesity or type 2 diabetes. Christopher Gross, a foot and ankle surgeon at the Medical University of South Carolina, said the findings did not support fears that rapid weight loss from these medicines necessarily weakens bone.
In one cohort study, Gross and colleagues analysed data from a large federated electronic health record network covering 348,486 patients aged 50 to 90 with type 2 diabetes who were prescribed either a GLP-1 receptor agonist or a dipeptidyl peptidase-4 inhibitor. After matching patients by demographics, underlying conditions and medicines, the researchers found lower fracture risk at bone-rich sites such as the hip and spine among GLP-1 users, but no meaningful difference in ankle fractures. Gross told Healio that the pattern looked site-specific, rather than a broad increase or decrease across all injuries.
A second study used TriNetX data to examine 283,938 adults with obesity but without type 2 diabetes who were prescribed GLP-1 drugs, matched against the same number who were not. Over five years, the GLP-1 group showed a 30% lower risk of fragility fractures overall, with the biggest reductions seen in the proximal femur, forearm, upper arm and vertebrae. Patients with obesity appeared to benefit most, compared with those who were merely overweight or of normal weight.
The results fit with a growing body of earlier research. A 2025 meta-analysis of randomised controlled trials published on PubMed found no increased fracture risk with GLP-1 treatment in type 2 diabetes and reported modest improvements in bone mineral density and some bone turnover markers. Earlier meta-analyses and comparative studies have also pointed in the same direction, including a JAMA Network Open analysis that found lower three-year fragility fracture risk after GLP-1 initiation compared with dipeptidyl peptidase-4 inhibitors. Even so, Gross said the data are not strong enough to justify using these drugs specifically to prevent fractures, and he said older patients losing weight should still have their muscle and bone health reviewed together.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
